蘇州生物醫藥轉化工程中心
現任中國科學院生物物理所研究員，中科院生物物理所蛋白質與多肽藥物創新平臺執行主任，2017年中科院率先行動“百人計劃”學術帥才（A類）獲得者。 王峰博士曾在美國加州生物醫藥研究所(Calibr)、斯克利普斯研究所(The Scripps Research Institute)和諾華制藥集團(Novartis)長期從事生物醫藥研究工作。在美國加州生物醫藥研究所擔任首席研究員期間，負責生物大分子創新藥物的前期研發，主持了30多個研發項目，部分臨床候選藥物已轉讓給大型國際藥企進行產品開發，在藥物篩選、設計和優化等方面積累了大量的經驗，并擁有多個藥物研發的新平臺技術。
Feng Wang, PhD, Director, Suzhou Institute for Biomedical Research; Associate director and principal investigator at Key Laboratory of Protein and Peptide Therapeutics of Institute of Biophysics (IBP), Chinese Academy of Sciences (CAS). His research work focuses on developing new methods to identify and design novel antibody and antibody derivatives as therapeutics. Before joining IBP, Dr. Wang worked with Dr. Peter Schultz to establish California Institute for Biomedical Research (CaliBR) in 2012. He was principal investigator in charge of the group of protein therapeutics from 2012 to 2017. His work is currently supported by multiple state funding agencies and was funded by Bill & Melinda Gates Foundation, Juvenile Diabetes Research Foundation (JDRF), Pfizer and Merck & CO. Dr. Wang got his Ph.D in biochemistry at TAMU and performed his postdoc research work at The Scripps Research Institute, La Jolla, California.
中國科學院生物物理研究所客座研究員，擁有多年臨床醫學經驗，于2000 年加入美國國際諾華制藥集團，在諾華基因組研究所(GNF，美國加州圣地亞哥)工作的十三年里，參與了多項諾華全球新藥研發項目。張捷博士是一位熟悉中國和歐美醫藥企業運營，具備企業戰略規劃制定和執行、醫藥創新和產業化等多方面能力的復合型人才。
Jay Zhang M.D./Ph.D, Deputy Director, Suzhou Institute for Biomedical Research, IBP, CAS; Dr. Zhang has over thirteen years’ experience in research and development at Novartis, with extensive experience in leading strategic planning & implementation process for biotech start-ups with strong global orientation.
管理團隊
MANAGEMENT TEAM
蘇州生物醫藥轉化工程中心
蘇州生物醫藥轉化工程中心（以下簡稱“轉化中心”）以生物醫藥創新藥為主導，專注于從新藥候選物的篩選優化到臨床前研究等新藥研發的重要階段，力爭成為具有國際 影響力的創新藥物研發中心。
